Top drug regulator Richard Pazdur filed papers to retire from the Food and Drug Administration at the end of this month, but ...

Weeks after being named head of CDER, Pazdur has submitted paperwork to step down at the end of the month, exacerbating what’s already been a turbulent year at the FDA.

Longtime FDA oncology leader and newly appointed Center for Drug Evaluation and Research director Richard Pazdur has filed ...

Several news outlets, including Politico, CNN and the Washington Post, reported on December 2 that Food and Drug Administration lead drug regulator Richard Pazdur will resign, despite being only weeks ...

Food and Drug Administration'‌s newly appointed head of the drug evaluation ‌department, Richard Pazdur, is set to retire ...

Long-serving FDA figure Richard Pazdur has filed papers to retire, shortly after being appointed to lead the agency's Center ...

Richard Pazdur, the US Food and Drug Administration’s lead drug regulator, plans to retire from the agency only weeks after ...

On , The US Food and Drug Administration issued draft guidance identifying specific types of monoclonal antibody products for which the agency believes six-month toxicity testing in non-human primates ...

Mere weeks after being named the nation’s top drug regulator, Richard Pazdur, M.D., is taking steps to retire as head of the FDA’s Center for Drug Evaluation and Research at the end of this month, | ...

Morgan Stanley raised the firm’s price target on Roche (RHHBY) to CHF 290 from CHF 255 and keeps an Underweight rating on the shares. Published ...

Berenberg raised the firm’s price target on Roche (RHHBY) to CHF 300 from CHF 290 and keeps a Hold rating on the shares. Published first on TheFly ...

Richard Pazdur, the US Food and Drug Administration’s lead drug regulator, plans to retire from the agency only weeks after ...